Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mononuclear cells (UTHealth Houston, b3b012)
- Development stage
- Unknown
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous bone marrow mononuclear cells (BM-MNCs) are a heterogeneous population of cells, including mesenchymal stem cells, hematopoietic progenitor cells, and endothelial progenitor cells, harvested from a patient's own bone marrow. Developed by The University of Texas Health Science Center at Houston, this cell therapy is administered intravenously within 24 to 72 hours following an acute ischemic stroke. The therapy aims to mitigate the inflammatory response and promote neurorecovery through paracrine effects and the modulation of the systemic immune response to brain injury. The mononuclear cell fraction is isolated at a Good Manufacturing Practices facility before being reinfused at a target dose of up to 10 million cells per kilogram.
- Other names
- BM-MNCsautologous mononuclear bone marrow cellsbone marrow mononuclear cells
Beyond the preview
Go deeper on autologous bone marrow mononuclear cells (UTHealth Houston, b3b012).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mononuclear cells (UTHealth Houston, b3b012).